775d Ustekinumab Versus Adalimumab for Induction and Maintenance Therapy in Moderate-to-Severe Crohn’s Disease: The SEAVUE Study
Bruce E. Sands(Icahn School of Medicine at Mount Sinai), William J. Sandborn(University of San Diego), Remo Panaccione(University of Calgary), Christopher Gasink(Janssen (United States)), Stephen B. Hanauer(Northwestern University), Tanja Kuehbacher, Peter M. Irving(Guy's and St Thomas' NHS Foundation Trust), Vipul Jairath(McMaster University), James D. Lewis(University of Pennsylvania), Silvio Danese(IRCCS Ospedale San Raffaele), Matthieu Allez(Inserm), Edward V. Loftus(Mayo Clinic), James Izanec(Janssen (United States)), Long-Long Gao(Janssen (United States)), Timothy Hoops(Johnson & Johnson (United States)), Andrew Greenspan(Indiana Cancer Consortium), Ellen Scherl(NewYork–Presbyterian Hospital), Emese Mihály(Semmelweis University), О. Б. Щукина(City Clinical Hospital No 31)
Cited by 30
Related Papers
Linking Long-Term Dietary Patterns with Gut Microbial Enterotypes
|Science|2011|6.6k
Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis
|Nature Medicine|2013|4.4k
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k